Bolt Biotherapeutics Inc (NAS:BOLT)
$ 0.626 -0.0039 (-0.62%) Market Cap: 23.96 Mil Enterprise Value: -11.66 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 40/100

Bolt Biotherapeutics Inc CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle Transcript

Sep 23, 2020 / NTS GMT
Matt Pillar
Life Science Connect - Moderator

Welcome to the Business of Biotech. If you've listened to our summer executive sessions, you'll be familiar with Bolt Biotherapeutics. We had a great conversation with Bolt, CEO, Randy Schatzman, about how is keeping the money train rolling despite the disruption of COVID-19.

On today's episode, we're jumping into CMC and patient centricity considerations with two of Dr. Schatzman's brightest stars; doctors Edith Pérez, CMO; and Nathan Ihle, CTO at Bolt. This was a particularly fun and informative episode because it really illustrates the importance of a connection that can be easy to lose that between the technicalities of CMC considerations in preparation for first-in-human studies and the patient first responsibilities that make the Chief Medical Officer role so important for clinical stage biotechs. Let's give it a listen.

In this episode of the Business of Biotech, I am thrilled to sit down with two of Bolt Biotherapeutics' finest new in both cases, stars, Dr. Edith Pérez, who just joined the company as Chief Medical Officer; and Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot